BCL2 and cancer: Furthermore, puromycin enhanced the inhibition of c-Myc and Bcl-2 and activation of p53 by doxorubicin in HCT116 cells, suggesting a potent combination therapy of puromycin and doxorubicin especially in p53 wild-type cancers, though further study is required in animal studies and human clinical trials in the future.